This pharma stock soared 2x in one year. Is there still time to invest?

The Indian pharmaceutical industry has given the market several prominent wealth creators over the years. Gujarat Themis Biosyn, a small-cap pharma player, might be on its way to becoming a new addition to this illustrious list. In the last five years, the stock witnessed remarkable financial growth, with its revenue and profit after tax growing at an annual rate of 31 and 62 per cent, respectively. Further, its operating profit margin zoomed by over 21 percentage points in FY20 and has remained steady. This impressive performance did not go unnoticed. Its share price grew by 159 per cent in the last 12 months (as of May 18, 2024). An impressive journey The company's revenue has jumped by almost four times since FY19 TTM FY23 FY22 FY21 FY20 FY19 Revenue (Rs cr) 156 149 115 91 85 41 Operating profit (Rs cr) 70 72 56 39 30 6 CFO (Rs cr) 57 40 40 11 1 1 Profit after tax (Rs cr) 55 58 44 30